longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Zenas Biopharma

ZBIO

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -4.24, within the reasonable range, cheaper than 39.08% of the time in the past 1 years, and the industry ranks 344/601, the industry Median -2.44.

-4.24xP/E
$31.50Stock price
$-7.43Earnings per share
-4.24xP/E
Stock price$31.50Earnings per share$-7.43

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-4.61x
Typical range
-7.45x–-3.31x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-57.45x148.77%$186.13B
MRNAUSModerna
-19.52x15.47%$61.50B
CSLLYUSCSL Limited
-23.10x--$59.58B
NTRAUSNatera
-276.82x10.38%$53.25B
RVMDUSRevolution Medicines
-23.15x64.29%$40.93B
ROIVUSRoivant Sciences
-107.89x145.04%$28.73B
INSMUSInsmed
-29.94x74.48%$26.21B
BNTXUSBioNTech SE
-12.33x19.17%$24.13B
SMMTUSSummit Therapeutics
-16.63x18.58%$14.24B
BBIOUSBridgebio Pharma
-18.82x28.57%$13.02B
MDGLUSMadrigal Pharma
-37.77x50.86%$12.28B
TWSTUSTwist Bioscience
-80.41x24.61%$10.99B
KYMRUSKymera Therapeutics
-32.68x4.94%$9.79B
CYTKUSCytokinetics
-10.70x6.37%$9.56B
ARWRUSArrowHead Pharma
-29.35x36,308.30%$9.39B
ABVXUSAbivax SA
-23.59x32.59%$9.16B
IBRXUSImmunityBio
-9.06x152.63%$8.99B
PCVXUSVaxcyte
-8.13x48.80%$8.65B
PRAXUSPraxis Precision Medicines
-24.61x3.05%$8.35B
SYREUSSpyre Therapeutics
-52.98x47.81%$7.96B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.